Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.04
AIQ's Cash-to-Debt is ranked lower than
96% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. AIQ: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
AIQ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.06 Max: 0.2
Current: 0.04
0.01
0.2
Equity-to-Asset -0.21
AIQ's Equity-to-Asset is ranked lower than
95% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. AIQ: -0.21 )
Ranked among companies with meaningful Equity-to-Asset only.
AIQ' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.39  Med: -0.1 Max: 0.04
Current: -0.21
-0.39
0.04
Debt-to-Equity -3.88
AIQ's Debt-to-Equity is ranked lower than
99.99% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. AIQ: -3.88 )
Ranked among companies with meaningful Debt-to-Equity only.
AIQ' s Debt-to-Equity Range Over the Past 10 Years
Min: -367.24  Med: -3.88 Max: 525.92
Current: -3.88
-367.24
525.92
Debt-to-EBITDA 4.41
AIQ's Debt-to-EBITDA is ranked lower than
82% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. AIQ: 4.41 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AIQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.83  Med: 4.42 Max: 6.4
Current: 4.41
-15.83
6.4
Interest Coverage 1.53
AIQ's Interest Coverage is ranked lower than
92% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. AIQ: 1.53 )
Ranked among companies with meaningful Interest Coverage only.
AIQ' s Interest Coverage Range Over the Past 10 Years
Min: 0.27  Med: 1.38 Max: 2.08
Current: 1.53
0.27
2.08
Piotroski F-Score: 3
Altman Z-Score: 0.76
Beneish M-Score: -3.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 10.44
AIQ's Operating Margin % is ranked higher than
69% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. AIQ: 10.44 )
Ranked among companies with meaningful Operating Margin % only.
AIQ' s Operating Margin % Range Over the Past 10 Years
Min: -29.79  Med: 9.43 Max: 14.34
Current: 10.44
-29.79
14.34
Net Margin % -0.32
AIQ's Net Margin % is ranked higher than
51% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. AIQ: -0.32 )
Ranked among companies with meaningful Net Margin % only.
AIQ' s Net Margin % Range Over the Past 10 Years
Min: -32.43  Med: 0.1 Max: 3.65
Current: -0.32
-32.43
3.65
ROA % -0.27
AIQ's ROA % is ranked higher than
54% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. AIQ: -0.27 )
Ranked among companies with meaningful ROA % only.
AIQ' s ROA % Range Over the Past 10 Years
Min: -21.65  Med: 0.07 Max: 2.18
Current: -0.27
-21.65
2.18
ROC (Joel Greenblatt) % 25.92
AIQ's ROC (Joel Greenblatt) % is ranked higher than
71% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. AIQ: 25.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AIQ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -47.29  Med: 16.89 Max: 28.87
Current: 25.92
-47.29
28.87
3-Year Revenue Growth Rate 3.00
AIQ's 3-Year Revenue Growth Rate is ranked lower than
57% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. AIQ: 3.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AIQ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.7  Med: 1.3 Max: 27
Current: 3
-4.7
27
3-Year EBITDA Growth Rate 7.60
AIQ's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. AIQ: 7.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AIQ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: -3.1 Max: 151.8
Current: 7.6
-20.5
151.8
GuruFocus has detected 5 Warning Signs with Alliance HealthCare Services Inc AIQ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AIQ's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

AIQ Guru Trades in Q4 2016

Chuck Royce 30,073 sh (+33.55%)
Jim Simons 762,960 sh (+4.95%)
» More
Q1 2017

AIQ Guru Trades in Q1 2017

Jim Simons 795,460 sh (+4.26%)
Chuck Royce 30,073 sh (unchged)
» More
Q2 2017

AIQ Guru Trades in Q2 2017

Jim Simons 857,760 sh (+7.83%)
Chuck Royce 26,974 sh (-10.30%)
» More
Q3 2017

AIQ Guru Trades in Q3 2017

Jim Simons Sold Out
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AIQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 622310    SIC: 8069
Compare:XPAR:ALMDT, LSE:MXCT, NAS:TTOO, HKSE:00928, TSE:7707, OSTO:CRAD B, SGX:P8A, AMEX:PTN, TSE:6678, OSTO:BOUL, LSE:EKF, XMCE:CBAV, TSE:4595, PHS:DNA, NAS:CDNA, NAS:ONVO, XKRX:950140, TSE:4671, XTER:ECX, NAS:TRIB » details
Traded in other countries:AI6M.Germany,
Headquarter Location:USA
Alliance HealthCare Services Inc provides outsourced healthcare services to hospitals and providers. It also operates freestanding outpatient radiology, oncology and interventional clinics, and Ambulatory Surgical Centers.

Alliance HealthCare Services Inc is a national provider of outsourced medical services, including radiology, oncology and interventional. The company reports in three segments: Radiology, Oncology, and Interventional. Radiology Division provides a full continuum of diagnostic imaging capabilities from mobile to fixed-site to service line management to hospitals and provider groups. This segment is also the highest revenue generating segment for the company. Alliance HealthCare provides a full continuum of services: systems, technologists to operate the systems, sales, and marketing, overall management of services and fixed-site operations including outpatient clinics and Ambulatory Surgical Centers.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 6.72
AIQ's Price-to-Owner-Earnings is ranked higher than
97% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. AIQ: 6.72 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AIQ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.52  Med: 6.85 Max: 22.32
Current: 6.72
1.52
22.32
PS Ratio 0.27
AIQ's PS Ratio is ranked higher than
98% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. AIQ: 0.27 )
Ranked among companies with meaningful PS Ratio only.
AIQ' s PS Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.51 Max: 1.29
Current: 0.27
0.08
1.29
Price-to-Free-Cash-Flow 2.60
AIQ's Price-to-Free-Cash-Flow is ranked higher than
99% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. AIQ: 2.60 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AIQ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.74  Med: 4.58 Max: 11.8
Current: 2.6
0.74
11.8
Price-to-Operating-Cash-Flow 1.42
AIQ's Price-to-Operating-Cash-Flow is ranked higher than
99% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. AIQ: 1.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AIQ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.44  Med: 2.08 Max: 4.75
Current: 1.42
0.44
4.75
EV-to-EBIT 14.47
AIQ's EV-to-EBIT is ranked higher than
83% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. AIQ: 14.47 )
Ranked among companies with meaningful EV-to-EBIT only.
AIQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -342.9  Med: 14.9 Max: 77.4
Current: 14.47
-342.9
77.4
EV-to-EBITDA 6.44
AIQ's EV-to-EBITDA is ranked higher than
95% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. AIQ: 6.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
AIQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.1  Med: 6.4 Max: 10.2
Current: 6.44
-18.1
10.2
EV-to-Revenue 1.51
AIQ's EV-to-Revenue is ranked higher than
86% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. AIQ: 1.51 )
Ranked among companies with meaningful EV-to-Revenue only.
AIQ' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 1.7 Max: 2.5
Current: 1.51
1.3
2.5
Current Ratio 1.00
AIQ's Current Ratio is ranked lower than
88% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. AIQ: 1.00 )
Ranked among companies with meaningful Current Ratio only.
AIQ' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.55 Max: 2.87
Current: 1
1
2.87
Quick Ratio 1.00
AIQ's Quick Ratio is ranked lower than
82% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. AIQ: 1.00 )
Ranked among companies with meaningful Quick Ratio only.
AIQ' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.55 Max: 2.87
Current: 1
1
2.87
Days Sales Outstanding 56.40
AIQ's Days Sales Outstanding is ranked higher than
61% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. AIQ: 56.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
AIQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.7  Med: 50.62 Max: 56.49
Current: 56.4
44.7
56.49
Days Payable 26.55
AIQ's Days Payable is ranked lower than
83% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. AIQ: 26.55 )
Ranked among companies with meaningful Days Payable only.
AIQ' s Days Payable Range Over the Past 10 Years
Min: 18.28  Med: 28.73 Max: 36
Current: 26.55
18.28
36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.40
AIQ's 3-Year Average Share Buyback Ratio is ranked higher than
80% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. AIQ: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AIQ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.7  Med: -1.2 Max: 7.1
Current: -0.4
-67.7
7.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.47
AIQ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. AIQ: 0.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AIQ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.17  Med: 0.66 Max: 4.31
Current: 0.47
0.17
4.31
Price-to-Median-PS-Value 0.53
AIQ's Price-to-Median-PS-Value is ranked higher than
81% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. AIQ: 0.53 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AIQ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.21  Med: 1.15 Max: 4.14
Current: 0.53
0.21
4.14
Earnings Yield (Greenblatt) % 6.91
AIQ's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. AIQ: 6.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AIQ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -24.2  Med: 6.1 Max: 11.2
Current: 6.91
-24.2
11.2
Forward Rate of Return (Yacktman) % 33.81
AIQ's Forward Rate of Return (Yacktman) % is ranked higher than
91% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. AIQ: 33.81 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AIQ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7  Med: 19.2 Max: 148.5
Current: 33.81
7
148.5

More Statistics

Revenue (TTM) (Mil) $523.71
EPS (TTM) $ -0.17
Short Percentage of Float0.97%
52-Week Range $6.15 - 13.60
Shares Outstanding (Mil)10.83

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}